These experiments may impact patient care by increasing our understanding of mechanisms of trastuzumab emtansine (T-DM1)-induced thrombocytopenia. T-DM1
Introduction
One of the major limitations of systemic chemotherapy for cancer is the development of dose-limiting toxicity, caused by the exposure of nontumor cells to cytotoxic agents. Antibody-drug conjugates (ADCs) are composed of a cytotoxic agent conjugated to a targeted antibody via a covalent linker (1) . ADCs are designed to deliver this cytotoxic agent selectively to tumor cells, thereby minimizing systemic toxicity.
Trastuzumab emtansine (T-DM1) is an ADC comprising the cytotoxic agent DM1 conjugated via a stable thioether linker to the humanized human epidermal growth factor receptor 2 (HER2)-targeted monoclonal antibody trastuzumab (2) . T-DM1 binds to the HER2 receptor with an affinity similar to that of unconjugated trastuzumab (3) . T-DM1 is internalized, and the active catabolite lysine- T-DM1 is approved for the treatment of patients with previously treated metastatic breast cancer. T-DM1 has been generally well tolerated with a lower incidence of grade ≥3 adverse events compared with trastuzumab plus docetaxel (46.4% vs.
90.9%) (5) and lapatinib plus capecitabine (40.8% vs. 57.0%) (6) . Thrombocytopenia
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Author Manuscript Published OnlineFirst on November 4, 2014; DOI: 10.1158/1078-0432.CCR- was the dose-limiting toxicity with T-DM1 (10) and grade ≥3 thrombocytopenia was observed in 4.7% (7) to 12.9% (6) of patients in phase III studies. In most patients who receive T-DM1 once every 21 days, concentrations of circulating platelets show a pattern of cyclic decline, often below the normal range, followed by recovery to normal prior to the next dose (6, (8) (9) (10) . While the predose platelet count remains consistent for the duration of the treatment course in many patients, others exhibit a slow downward drift in predose platelet counts with repeated cycles of T-DM1 (9) .
Other hematologic lineages appear to be relatively unaffected by T-DM1, with low rates of severe anemia, leukopenia, and neutropenia (5, 6) . As with leukocytes and erythrocytes, platelets are not thought to express HER2 (11).
The aim of the current study is to investigate potential mechanisms of T-DM1-induced thrombocytopenia by evaluating the effect of T-DM1 on platelet function and on the differentiation of megakaryocytes (MKs) derived in vitro from human HSCs.
Materials and Methods

Platelet isolation
Platelet rich plasma (PRP) was isolated by low speed centrifugation of whole blood from normal human donors drawn into trisodium citrate containing bivalirudin and apyrase. For washed platelets (WPs), whole blood was obtained from normal human volunteers into acid citrate dextrose. WPs were prepared as described (12) by centrifugation twice in CGS buffer. Platelets were resuspended in Tyrodes-Hepes buffer at 2 × 10 8 /mL for further experiments. For activation experiments, CaCl 2 (final concentration 1 mM) was added, and platelets were allowed to rest for 15 minutes at room temperature before use. 
Platelet activation
Platelet activation was measured by detecting activated GPIIb/IIIa (i.e., PAC1 binding) and P-selectin (CD62P) expression using flow cytometry. WP (100 µL of 2 × 10 8 /mL) or PRP were aliquoted into 96-well conical well plates and activated at 4°C for 10 minutes using collagen (1 to 10 μg/mL, Chronolog, Havertown, PA) or TRAP (~1 μM, Sigma-Aldrich, St. Louis, MO) as a positive control, or various test antibodies. Test antibodies included trastuzumab, T-DM1, and the control nonspecific ADC 5B6-DM1 (13) . All three test antibodies are of IgG1 isotype.
Platelets were diluted 1:1 with ice cold Tyrodes-Hepes buffer and aliquoted (40 uL aliquots) into triplicate wells containing PE-conjugated anti-CD41 antibody to identify platelets (3 µL) or isotype control and either FITC-conjugated anti-CD62P antibody or FITC-conjugated anti-PAC1 antibody (3 µL) or respective FITC-conjugated isotype controls. Following a one-hour incubation at 4°C, platelets were diluted and assessed by flow cytometry using a FACSCalibur (BD Biosciences, San Jose, CA).
For experiments assessing the effect of the various test antibodies on agonistinduced activation, WP or PRP were preincubated with the test antibodies for 30 minutes at 4°C and then collagen or TRAP was added for an additional 10-minute incubation.
Platelet aggregation
WP (500 μL, 2 × 10 8 /mL) or PRP (500 μL, ~2 × 10 days to obtain multinucleated MKs. Evaluation of the MK differentiation process was performed by flow cytometry, using the MK-lineage specific markers CD41 and CD61 ( Supplementary Fig. S1 ). To obtain mature MKs, day 14 MKs (i.e., immature MKs) were cultured in the same medium for an additional 14 to 16 days ( Supplementary Fig. S1B ).
MK production and cell viability
Determination of IC 50
To determine the IC 50 of T-DM1 on immature MKs, CD133 were assessed in triplicate for ATP levels as described above.
Based on these experiments, a concentration of 6.25 μg/mL was used for all conjugates and antibodies for subsequent experiments (except where noted). acetonitrile/water (120 µL) containing maytansine (7.5 nM) as an internal standard.
Flow cytometry analysis
To measure DM1, an aliquot (30 µL) of the MK lysates was first treated at 37°C for 15 minutes at pH 6.6 with Tris(2-carboxyethyl)phosphine (1.25 µL, 26 mM; ThermoScientific Pierce, Rockford, IL) to release any disulfide-bound DM1, and then extracted as described above. The free sulfhydryl on DM1 was blocked by conversion to DM1 N-ethyl maleimide (NEM) (7.9 µL, 25 mM, Sigma-Aldrich, St 
Uptake of radiolabeled antibodies
To assess the contribution of FcγRIIa, the Fc receptor that is expressed on human MKs (14) and platelets (15) , to the uptake of T-DM1, we evaluated the uptake of both the parent antibody trastuzumab and a mutant version of trastuzumab (trastuzumab-DANA), in which the Fc region has two mutations, D265A and N297A (16) , such that it no longer binds Fcγ receptor. Both forms of trastuzumab were radioiodinated with 125 I using Iodogen as previously described (17) . The uptake and catabolism of labeled antibodies were determined as follows. At day 0, labeled antibodies (1.0 μCi/mL) were added to the cells (4 × 10 6 ) at the indicated time points. Cells were harvested and washed three times (0.5 mL each). Incubation media and wash supernatants were collected and used for radioactivity determination. Radioactivity associated with the cell pellet, as well as the media and washes, were quantified by gamma scintigraphy. The percent radioactivity per 10 6 cells for each fraction was determined.
Results
Effect of T-DM1 on platelet activation and aggregation
To determine if the thrombocytopenia observed in T-DM1-treated patients was caused, at least in part, by a direct effect on mature platelets, we evaluated the effects of T-DM1 and DM1 on the function of platelets isolated from normal donors.
Platelets were isolated and utilized either as PRP or WP, as described in the Methods section, and incubated with T-DM1, DM1, or controls. Neither T-DM1 nor DM1 directly induced platelet activation in PRP, as measured by the expression of activated GPIIb/IIIa (i.e., PAC1 binding) (Fig. 1A) and CD62P (Fig. 1B) . Expression of these activation markers were similar between resting platelets and platelets treated with T-DM1, trastuzumab, control ADCs, and DM1.
T-DM1 also did not directly induce platelet aggregation in PRP (Fig. 1C ) or in WP ( Supplementary Fig. S2 ). To determine whether DM1 induces platelet aggregation,
we exposed PRP to DM1 concentrations in the range of those measured in patients treated with T-DM1. On average, maximum systemic plasma DM1 concentrations
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Next we evaluated the impact of T-DM1 and DM1 on agonist-induced platelet activation and aggregation. Neither T-DM1 nor DM1 had an effect on agonistinduced platelet activation in PRP. Increased PAC1 binding and CD62 expression induced by collagen or TRAP were unaffected by pretreatment with T-DM1, trastuzumab, or control ADC ( Fig. 2A and 2B ), or by clinically relevant concentrations of DM1 (Fig. 2C and 2D) . Similarly, neither T-DM1 (Fig. 2E) nor clinically relevant concentrations of DM1 affected agonist-induced platelet aggregation (Fig. 2F) .
However, at high concentrations (i.e., 100 μM, which is ~12,500-fold higher than concentrations measured in patient samples), DM1 inhibited agonist-induced platelet aggregation by 77% (Supplementary Fig. S3 ).
Effect of T-DM1 on MK differentiation from HSCs
In the absence of a direct, observable effect on platelet activation or aggregation, we evaluated the potential effects of T-DM1 on generation of MKs from HSCs (i.e., 
Morphology
On day 9 of differentiation, trastuzumab had no observable effect on MK morphology compared with vehicle control (Supplementary Figs. S4A and S4B) . However, treatment with the ADCs T-DM1 or 5B6-DM1 during HSC differentiation altered the cell morphology, inducing a vacuolated morphology consistent with MK death (20) ( Supplementary Figs. S4C and S4D, respectively) .
Overall viability
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Differentiation of HSCs into MKs can be monitored via the expression of the specific MK markers CD41 and CD61. In our in vitro model, the percentage of CD41-expressing cells increases over time during differentiation, reaching approximately 70% to 90% at day 14, depending on the donor (Supplementary Fig. S1 ).
We investigated the effect of T-DM1 on HSCs differentiating into MKs and determined the dose-response relationship of this effect (Fig. 3A) . T-DM1 appeared to decrease the number of MKs by day 3 with an approximate IC 50 of 7 μg/mL (~50 nM). Decreased MK viability after T-DM1 treatment was more pronounced at day 6 with an IC 50 of approximately 3 μg/mL (~20 nM), and the IC 50 remained stable through day 14. Trastuzumab did not decrease MK viability at any dose or time point, while the control ADC 5B6-DM1 showed similar viability decreases as T-DM1, suggesting that the T-DM1 effect was due to its DM1 component and not its trastuzumab component.
Viability of immature MKs
To further investigate the effect of T-DM1 on differentiation of HSCs into MKs, we used flow cytometry to measure total cell number, number of MKs (i.e., CD41+/CD61+ cells), and cell viability at day 3, 6, 9, and 14 of differentiation (Figs.   3B, 3D ). The number of vehicle-and trastuzumab-treated cells increased over the 14-day time course, reaching a maximal increase of 120-fold over day 0. Continuous exposure of HSCs to DM1 conjugates resulted in a marked decrease relative to vehicle-treated and trastuzumab-treated cells in the percentage of MKs (Fig. 3B ).
Decreased MK production was observed as early as day 6 (~50%), and MK numbers decreased further at day 9 (~90%) and remained at this level at day 14. These changes in MK cell number correlated with a decrease in cell viability (Fig. 3D) .
These results suggest that decreased cell viability of HSCs differentiating into MKs induced by T-DM1 is mediated by the chemotherapeutic component of T-DM1 (i.e., DM1) and not by the antibody (i.e., trastuzumab).
Viability of maturing MKs
We conducted similar experiments to determine the effect of T-DM1 on maturing MKs (i.e., day 14-28 of differentiation). By day 28, the number of control-and trastuzumab-treated MKs had increased by ~100% compared with day 14 controland trastuzumab-treated cells (Fig. 3C) . As early as day 20, there was an observable reduction in MK cell number (~40%) in the T-DM1-and 5B6-DM1-treated cells. MK numbers decreased further at day 23 (~75%) and remained at this level at day 28 though this decrease in MK cell number was not as great as that seen in differentiating MKs. The decreases in MK cell number correlated with a decrease in cell viability (Fig. 3E) .
Taken together, these data suggest that T-DM1 has a cytotoxic effect on both differentiating and maturing MKs that is mediated by its DM1 component and that the effect is more pronounced in differentiating MKs than in maturing MKs.
Effect of T-DM1 on MK ploidy
To further investigate the effect of T-DM1 on MK differentiation from HSCs, we used flow cytometry to evaluate cell ploidy over time (Fig. 4) . We observed the expected 
MK uptake and catabolism of T-DM1
To determine if the reduction in MK number and the arresting of MK development following exposure to T-DM1 was due to the uptake of T-DM1, we assessed the time course of T-[ Table 1 . These data are consistent with the viability data demonstrating that precursor MKs (i.e., differentiating MKs), are more sensitive to treatment with DM1-containing antibodies than maturing MKs. In contrast to its pathway in tumor cells (4), T-DM1 was not detectable in lysosomes, as indicated by a lack of co-staining of T-DM1 and the lysosomal marker Cy3-LAMP1 (Supplementary Fig. S5B ).
To determine if the uptake of T-DM1 was mediated (completely or in part) through HER2, we first determined whether isolated MK lineage cells (day 14) express HER2. HER2 mRNA was not detected in platelets (Supplementary Fig. S6A ) and was detected at only very low levels in CD61-and CD61+ MKs (0.09 and 0. To confirm that the uptake of T-DM1 into MKs is HER2-independent and at least partially mediated by FcγRIIa , we evaluated the MK uptake of trastuzumab using two different radioprobes, properties of the chelator, and therefore, the cell-associated 111 In represents overall antibody exposure (21) . The kinetics of uptake were compared with those of similarly labeled trastuzumab-DANA mutants that lack FcγR binding. At day 0, 111 Intrastuzumab-DANA uptake was less than 111 In-trastuzumab uptake by 88%, and 125 Itrastuzumab-DANA uptake was less than 125 I-trastuzumab uptake by 98% ( Figure   5D ). Similarly, at day 3 125 I-trastuzumab-DANA uptake was less than 125 Itrastuzumab uptake by 99% ( Figure 5E ). Both 125 I-and 111 In-labeled antibodies showed similar trends, indicating that differences in the internalization of the trastuzumab-DANA could not be ascribed to the probe. These data provide further support for an essential role for FcγRIIa in MK uptake of T-DM1.
Effect of T-DM1 on intracellular tubulin and actin microfilaments in maturing MKs
Flow cytometry forward and side scatter analysis suggested that maturing MKs (i.e., 
Discussion
Drug-induced thrombocytopenia is relatively common and has been described for hundreds of agents. (22) This disorder primarily occurs via two distinct mechanisms: 1) decreased platelet production via cytotoxic effects on MKs and their precursors as observed with some cytotoxic chemotherapeutic agents (23) and 2) accelerated platelet destruction in peripheral blood via immune-mediated thrombocytopenia (24) and as observed with a number of drug classes including non-steroidal antiinflammatories, and sulphonamides (24).
The present study suggests that the thrombocytopenia observed in some T-DM1-treated patients is not immune-mediated and may result from decreased platelet production which is consistent with inhibition of MK differentiation, with no direct functional effect on platelets. The most pronounced effects of T-DM1 appear to occur during the differentiation process from HSCs to MKs. Our data show that trastuzumab, T-DM1, and a control DM1-containing ADC were all internalized by MKs and that HER2 was not expressed on MKs or platelets. Internalization could be inhibited by either blockade of the interaction between FcγRIIa using anti-CD32 or by using the Fc mutant trastuzumab-DANA, which is unable to bind FcγR. 
Our data are consistent with a previous report which found-using different methods-that T-DM1 induced platelet decreases by decreasing platelet production via an effect on the cytoskeleton of differentiating MKs (13) . The proposed mechanism of decreased platelet production (ie, cytoskeletal disruption in differentiating MKs) is also consistent with our data, showing cytoskeletal disorganization in maturing MKs when they were subjected to prolonged T-DM1 exposure ( Supplementary Figs. S7B and S7D) . We also show effects in earlier stages of differentiation and speculate that this occurs via a similar mechanism. Our data differ from those reported by Thon et al. in that these investigators concluded that T-DM1-induced thrombocytopenia occurs via a mechanism that is both HER2-and FcγRIIa -independent, based on the controls used and due to the fact that mouse MKs and platelets do not express FcγRIIa (25). Our data clearly demonstrate an FcγRIIa-dependent mechanism of internalization of T-DM1 in human MKs.
Differences between the results found in the two studies could be attributed partly to differences in experimental methodologies and species differences.
T-DM1-mediated effects appeared to be more pronounced in differentiating MKs (i.e., day 0 to day 14 cells) than in maturing MKs (day 14 to day 28 cells).
Differentiating MKs bound, internalized, and catabolized T-DM1 to a much greater degree than maturing MKs. However, T-DM1 did have an effect on maturing MKs as noted, above. T-DM1 exposure resulted in decreased cell viability (but to a lesser extent than that seen in differentiating MKs) and induced disruption of the cytoskeletal structure in these cells.
The mechanisms of T-DM1-induced thrombocytopenia described here are consistent with the pattern of cyclic decline and rebound of platelet levels seen during treatment with T-DM1 (9, 10) . In most patients receiving T-DM1, platelet levels show an acute drop and reach a nadir during cycle 1 and return to baseline levels between doses (6, (8) (9) (10) . Some patients do exhibit a slow drift downward in platelet counts with repeated cycles of T-DM1, resembling the pattern induced by cumulative myelosuppression seen with other cytotoxic agents (9) . However, even in those patients with a slow downward shift in platelet levels over subsequent cycles, platelet counts tend to stabilize at a level less severe than grade 3 thrombocytopenia (9). Indeed, grade 3 or higher thrombocytopenia occurred in only 4.7% to 12.9% of patients in the phase III studies with T-DM1 (6, 7). The kinetics of thrombocytopenia seen during treatment suggest that T-DM1 affects a specific platelet precursor pool.
We further hypothesize that depletion of this pool results in either a shift in the equilibrium in the bone marrow to generate more platelet precursor cells to manage the platelet depletion (26) or that a new lineage that is less sensitive to T-DM1 becomes dominant and platelet counts stabilize (9), or both. This hypothesis is consistent with our in vitro studies which show a profound effect on platelet precursors (proliferating MKs).
In phase 3 studies of T-DM1 other severe hematological toxicities occurred with much lower frequency than thrombocytopenia. Grade ≥3 anemia occurred in 2.7% of patients, grade ≥3 neutropenia occurred in 2.0% to 2.5%, and grade ≥3 leucopenia occurred in <2% of patients (6, 7) . These clinical data are consistent with an FcγRIIa-dependent mechanism since FcγRIIa is expressed at relatively low (or absent) levels in CD34+ cells isolated from human cord blood (27) and in lymphocyte lineages in normal human bone marrow (28) . However CD32 is expressed in myeloid lineages (28) . It is interesting to speculate that the small fraction of patients who exhibit a slow downward drift in platelet counts over time may indeed have a polymorphism(s) in 
